CHEMOTHERAPY WITH DOCETAXEL PLUS NEDAPLATIN FOR RECURRENT HEAD AND NECK CARCINOMA

DOI 1 Citations 9 References

Bibliographic Information

Other Title
  • 再発頭頚部癌に対するＤｏｃｅｔａｘｅｌ，Ｎｅｄａｐｌａｔｉｎ併用療法についての検討

Search this article

Abstract

We assessed the effect of chemotherapy with Docetaxel (TXT) plus Nedaplatin (CDGP) for recurrent head and neck carcinoma, which had been considered to be refractory for Cisplatin (CDDP) plus 5-fluorouracil (5FU). The regimen of the chemotherapy was administration of intravenous drip of TXT 60mg/m2 for 1 hour and CDGP 70mg/m2 for 2 hours. Eight patients were enrolled including 3 oropharynx, 2 epipharynx, and one each of larynx, maxillary sinus, and submandibular gland. The pathological findings of 8 cases were 4 of squamous cell carcinoma, 2 of adenocarcinoma, and one each of synovial sarcoma and anaplastic carcinoma. The results were 1 Complete Response, 3 Partial Response, 2 Minimal Response, and 2 No Change. The overall response rate was 50%. Regarding side effects, bone marrow suppression was seen among most of the cases. Especially leucopenia and neutropenia were seen in 7 of 8 cases, to whom we administered G-CSF and they immediately recovered. So we considered that dose limiting toxicity was leucopenia and neutropenia. We concluded that chemotherapy with TXT plus CDGP for recurrent head and neck carcinoma is effective as secondline chemotherapy.

Journal

Citations (1)*help

See more

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top